<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03487276</url>
  </required_header>
  <id_info>
    <org_study_id>IFX-1-P2.4</org_study_id>
    <nct_id>NCT03487276</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)</brief_title>
  <acronym>SHINE</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InflaRx GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>InflaRx GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether IFX-1 is safe and effective in the&#xD;
      treatment of moderate to severe hidradenitis suppurativa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hidradenitis suppurativa (HS) is a chronic devastating skin disorder affecting areas rich in&#xD;
      apocrine glands. HS is diagnosed by its clinical features and its chronicity. It is&#xD;
      recognized by the presence of recurrent, painful, deep-seated, rounded nodules usually ending&#xD;
      in abscesses and sinus tracts with suppuration and hypertrophic scarring. As complement C5a&#xD;
      is involved in the underlying acute inflammatory responses, this study is set up based on the&#xD;
      hypothesis that IFX-1 might be able to block C5a induced pro-inflammatory effects such as&#xD;
      neutrophil activation and cytokine generation, potentially contributing to the local skin&#xD;
      inflammation and tissue damage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 26, 2018</start_date>
  <completion_date type="Actual">January 27, 2020</completion_date>
  <primary_completion_date type="Actual">May 27, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Hidradenitis Suppurativa Clinical Response (HiSCR) Determined at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The primary efficacy endpoint of the percentage of patients with HiSCR at Week 16 was analyzed using the multiple comparisons procedure-modelling (MCP-Mod) procedure. The definition for response to treatment based on HiSCR relative to Baseline was: at least 50% reduction in abscesses and inflammatory nodule (AN) count (over all anatomical regions) with no increase in number of abscesses and in number of draining fistulas.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Hidradenitis Suppurativa Clinical Response (HiSCR) Determined at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Endpoint of the percentage of patients with HiSCR at Week 12 was analyzed in the same way as the primary endpoint using the MCP-Mod procedure and the same definition of response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Flares Relative to Day 1</measure>
    <time_frame>From Day 1 until Day 309</time_frame>
    <description>The number of patients with flares analyzed in terms of ≥ 25% increase in abscess and inflammatory nodule (AN) count among patients with a minimum increase of 2 in AN count compared to Day 1 was analyzed by descriptive statistics by time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Modified Sartorius Score (mSS) From Day 1.</measure>
    <time_frame>From Day 1 until Day 309</time_frame>
    <description>The absolute change from Day 1 will be analyzed by descriptive statistics by time point. The mSS is a summation of HS lesions based on a number of factors including anatomical region, number and type of lesions, distance between relevant lesions and lesions clearly separated by normal skin in each region measured as HS clinical parameters. The scale title for mSS is points. The mSS has a minimum value of 0 and no upper limit. The higher the score the more severe is the disease/worse is the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Patient's Global Assessment of Skin Pain From Day 1.</measure>
    <time_frame>From Day 1 until Day 309</time_frame>
    <description>The absolute changes from baseline were analyzed by descriptive statistics by time point. The Numeric Rating Scale (NRS) was used to assess the worst skin pain due to HS. The scale title for the NRS is points. Ratings for this item range from a minimum of 0 points (no skin pain) to a maximum of 10 points (skin pain as bad as you can imagine). The higher the score the more severe the disease/worse is the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving NRS30</measure>
    <time_frame>From Day 1 until Day 309</time_frame>
    <description>This is a segmented numeric version of the visual analog scale in which a respondent selects a whole number (0-10) that best reflects the intensity of their pain. The scale title for the NRS is points. The minimum score is 0 points (No skin pain), and the maximum score is 10 points (Skin pain as bad as you can imagine). The higher the score the more severe is the disease/worse is the outcome. The number of patients with at least 30% reduction and at least 1 point reduction from Day 1 in Patients Global Assessment of Skin Pain are displayed. The analysis is based on the worst skin pain the patients reported at the respective visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving NRS50.</measure>
    <time_frame>From Day 1 until Day 309</time_frame>
    <description>This is a segmented numeric version of the visual analog scale in which a respondent selects a whole number (0-10) that best reflects the intensity of their pain. The scale title for NRS is points. The minimum score is 0 points (No skin pain), and the maximum score is 10 points (Skin pain as bad as you can imagine). The higher the score the more severe is the disease/worse is the outcome. The number of patients with at least 50% reduction and at least 1 point reduction from Day 1 in Patients Global Assessment of Skin Pain are displayed. The analysis is based on the worst skin pain the patients reported at the respective visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Dermatology Life Quality Index (DLQI) Score From Day 1.</measure>
    <time_frame>From Day 1 until Day 309</time_frame>
    <description>The changes from Day 1 will be analyzed by descriptive statistics by time point. A score is documented for each of the 10 DLQI items, ranging from 0 to 3 for each item. The scale title for DLQI is points. The total score is the sum of the responses to all 10 DLQI items, ranging from the minimum of 0 points to the maximum of 30 points. A higher score corresponds to worse health related quality of life/outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Parameters (Adverse Events) Will be Assessed.</measure>
    <time_frame>From Day 1 until Day 309</time_frame>
    <description>The number of patients with any treatment emergent adverse event (adverse events that started after first infusion of IMP) was analyzed by time point.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">179</enrollment>
  <condition>Hidradenitis Suppurativa (HS)</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minimum Dose IFX-1 (400 mg Q4W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose IFX-1 (800 mg Q4W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Medium Dose IFX-1 (800 mg Q2W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose IFX-1 (1200 mg Q2W)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IFX-1</intervention_name>
    <description>Single IV infusions of IFX-1 diluted in sodium chloride.</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>CaCP29</other_name>
    <other_name>Vilobelimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, ≥ 18 years of age&#xD;
&#xD;
          -  Written informed consent obtained from subject&#xD;
&#xD;
          -  Diagnosis of HS for at least 1 year&#xD;
&#xD;
          -  Moderate or severe HS, as indicated by HS lesions in at least 2 distinct areas, 1 of&#xD;
             which must be at least Hurley Stage II or Stage III&#xD;
&#xD;
          -  Inadequate response to at least 3 months of oral antibiotics, or intolerance to&#xD;
             antibiotics&#xD;
&#xD;
          -  Total abscess and inflammatory nodule (AN) count of ≥ 3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with adalimumab or another biologic product during the 24 weeks before&#xD;
             Screening&#xD;
&#xD;
          -  Subjects on permitted oral antibiotic treatment for HS (doxycycline or minocycline&#xD;
             only) who have not been on a stable dose during the 28 days before Screening&#xD;
&#xD;
          -  Subject received systemic non-biologic therapy for HS with potential therapeutic&#xD;
             impact for HS during the 28 days before Screening (other than permitted oral&#xD;
             antibiotics)&#xD;
&#xD;
          -  Prior treatment with any of the following medications during the 28 days before&#xD;
             Screening:&#xD;
&#xD;
               -  Any other systemic therapy for HS&#xD;
&#xD;
               -  Any iv anti-infective therapy&#xD;
&#xD;
               -  Phototherapy (ultraviolet B or psoralen and ultraviolet A)&#xD;
&#xD;
          -  History of heart disease or malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Othmar Zenker, CMO</last_name>
    <role>Study Director</role>
    <affiliation>InflaRx GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRx Investigational Site</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRx Investigational Site</name>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Saint John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 2H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4C 9M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Nice</city>
        <state>Alpes Maritimes</state>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Bordeaux</city>
        <state>Gironde</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <state>Haute Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Antony</city>
        <state>Hauts De Seine</state>
        <zip>92160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Nantes</city>
        <state>Loire Atlantique</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Darmstadt</city>
        <state>Hessen</state>
        <zip>64297</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein Westfalen</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Dessau</city>
        <state>Sachsen Anhalt</state>
        <zip>06847</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>115 25</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Thessaloníki</city>
        <zip>54645</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Kraków</city>
        <zip>30-033</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Kłodzko</city>
        <zip>57-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Wrocław</city>
        <zip>50-566</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Wrocław</city>
        <zip>51-318</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>InflaRX Investigational Site</name>
      <address>
        <city>Łódź</city>
        <zip>90-436</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 27, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2018</study_first_posted>
  <results_first_submitted>January 18, 2021</results_first_submitted>
  <results_first_submitted_qc>March 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2021</results_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hidradenitis suppurativa</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>complement factor C5a</keyword>
  <keyword>IFX-1</keyword>
  <keyword>hidradenitis Suppurativa Clinical Response</keyword>
  <keyword>Inflammation</keyword>
  <keyword>skin diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vilobelimab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03487276/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study consisted of a Main and an Extension Period. In the Main Period 175 subjects were planned to be randomized to receive double-blind treatment with IMP or Placebo in 1 of 5 treatment cohorts in a ratio of 1:1:1:1:1. The Extension Period started after the Week 16 Visit. According to the assessed HiSCR response at Week 16, patients were distributed to two IFX-1 dosing regimens: Week 16 HiSCR responders to 800 mg Q4W and Week 16 HiSCR non-responders to 800 mg Q2W.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>Placebo&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>Minimum Dose IFX-1 (400 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3</title>
          <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4</title>
          <description>Medium Dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 5</title>
          <description>High Dose IFX-1 (1200 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Period (16 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="31">One patient completed the Main Period but was lost to follow-up afterwards and not treated in the Extension Period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Extension Period (28 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="84"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Number of Patients in Cohort 1 (Main Period) Crossed Over to Cohort 3 or 4</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Number of Patients in Cohort 2 (Main Period) Crossed Over to Cohort 3 or 4</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Number of Patients in Cohort 3 (Main Period) Crossed Over to Cohort 3 or 4</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Number of Patients in Cohort 4 (Main Period) Crossed Over to Cohort 3 or 4</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Number of Patients in Cohort 5 (Main Period) Crossed Over to Cohort 3 or 4</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="67"/>
                <participants group_id="P4" count="54"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis performed for safety analysis set (SAS)</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>Placebo&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>Minimum Dose IFX-1&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3</title>
          <description>Low dose IFX-1&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4</title>
          <description>Medium Dose IFX-1&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 5</title>
          <description>High Dose IFX-1&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="36"/>
            <count group_id="B5" value="36"/>
            <count group_id="B6" value="177"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="174"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" lower_limit="27.0" upper_limit="42.5"/>
                    <measurement group_id="B2" value="39.0" lower_limit="33.0" upper_limit="45.0"/>
                    <measurement group_id="B3" value="35.0" lower_limit="25.0" upper_limit="46.0"/>
                    <measurement group_id="B4" value="37.0" lower_limit="31.0" upper_limit="46.0"/>
                    <measurement group_id="B5" value="33.5" lower_limit="27.5" upper_limit="41.0"/>
                    <measurement group_id="B6" value="36.0" lower_limit="29.0" upper_limit="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="170"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="152"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline AN (total abscess and inflammatory nodule) count</title>
          <units>lesions</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.5" lower_limit="5.0" upper_limit="15.0"/>
                    <measurement group_id="B2" value="9.0" lower_limit="6.0" upper_limit="15.0"/>
                    <measurement group_id="B3" value="8.0" lower_limit="7.0" upper_limit="17.0"/>
                    <measurement group_id="B4" value="10.0" lower_limit="6.0" upper_limit="16.0"/>
                    <measurement group_id="B5" value="12.5" lower_limit="5.5" upper_limit="15.5"/>
                    <measurement group_id="B6" value="9.0" lower_limit="6.0" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Hidradenitis Suppurativa Clinical Response (HiSCR) Determined at Week 16</title>
        <description>The primary efficacy endpoint of the percentage of patients with HiSCR at Week 16 was analyzed using the multiple comparisons procedure-modelling (MCP-Mod) procedure. The definition for response to treatment based on HiSCR relative to Baseline was: at least 50% reduction in abscesses and inflammatory nodule (AN) count (over all anatomical regions) with no increase in number of abscesses and in number of draining fistulas.</description>
        <time_frame>Week 16</time_frame>
        <population>Analysis was performed on the full analysis set (FAS) population</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Minimum Dose IFX-1 (400 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>Medium Dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>High Dose IFX-1 (1200 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Hidradenitis Suppurativa Clinical Response (HiSCR) Determined at Week 16</title>
          <description>The primary efficacy endpoint of the percentage of patients with HiSCR at Week 16 was analyzed using the multiple comparisons procedure-modelling (MCP-Mod) procedure. The definition for response to treatment based on HiSCR relative to Baseline was: at least 50% reduction in abscesses and inflammatory nodule (AN) count (over all anatomical regions) with no increase in number of abscesses and in number of draining fistulas.</description>
          <population>Analysis was performed on the full analysis set (FAS) population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>HiSCR Responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>HiSCR Non-responder</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Hidradenitis Suppurativa Clinical Response (HiSCR) Determined at Week 12</title>
        <description>Endpoint of the percentage of patients with HiSCR at Week 12 was analyzed in the same way as the primary endpoint using the MCP-Mod procedure and the same definition of response.</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was performed on the full analysis set (FAS) population. Only patients with non-missing assessment at Week 12 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Minimum Dose IFX-1 (400 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4</title>
            <description>Medium Dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5</title>
            <description>High Dose IFX-1 (1200 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Hidradenitis Suppurativa Clinical Response (HiSCR) Determined at Week 12</title>
          <description>Endpoint of the percentage of patients with HiSCR at Week 12 was analyzed in the same way as the primary endpoint using the MCP-Mod procedure and the same definition of response.</description>
          <population>Analysis was performed on the full analysis set (FAS) population. Only patients with non-missing assessment at Week 12 were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HiSCR Responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HiSCR Non-responder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Flares Relative to Day 1</title>
        <description>The number of patients with flares analyzed in terms of ≥ 25% increase in abscess and inflammatory nodule (AN) count among patients with a minimum increase of 2 in AN count compared to Day 1 was analyzed by descriptive statistics by time point.</description>
        <time_frame>From Day 1 until Day 309</time_frame>
        <population>For the Main Period the full analysis set was used for the analysis and results of Week 16 are displayed.&#xD;
For the Extension Period the safety analysis set was used for the analysis and results of week 44 are displayed.&#xD;
Only patients with non-missing assessment at the respective visit were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Main Period: Cohort 1</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Main Period: Cohort 2</title>
            <description>Minimum Dose IFX-1 (400 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O3">
            <title>Main Period: Cohort 3</title>
            <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O4">
            <title>Main Period: Cohort 4</title>
            <description>Medium Dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O5">
            <title>Main Period: Cohort 5</title>
            <description>High Dose IFX-1 (1200 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O6">
            <title>Extension Period: Cohort 3</title>
            <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O7">
            <title>Extension Period: Cohort 4</title>
            <description>Low dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Flares Relative to Day 1</title>
          <description>The number of patients with flares analyzed in terms of ≥ 25% increase in abscess and inflammatory nodule (AN) count among patients with a minimum increase of 2 in AN count compared to Day 1 was analyzed by descriptive statistics by time point.</description>
          <population>For the Main Period the full analysis set was used for the analysis and results of Week 16 are displayed.&#xD;
For the Extension Period the safety analysis set was used for the analysis and results of week 44 are displayed.&#xD;
Only patients with non-missing assessment at the respective visit were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="67"/>
                <count group_id="O7" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Patient with flares</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Patient without flares</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="64"/>
                    <measurement group_id="O7" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Modified Sartorius Score (mSS) From Day 1.</title>
        <description>The absolute change from Day 1 will be analyzed by descriptive statistics by time point. The mSS is a summation of HS lesions based on a number of factors including anatomical region, number and type of lesions, distance between relevant lesions and lesions clearly separated by normal skin in each region measured as HS clinical parameters. The scale title for mSS is points. The mSS has a minimum value of 0 and no upper limit. The higher the score the more severe is the disease/worse is the outcome.</description>
        <time_frame>From Day 1 until Day 309</time_frame>
        <population>For the Main Period the full analysis set was used for the analysis and results of Week 16 are displayed.&#xD;
For the Extension Period the safety analysis set was used for the analysis and results of week 44 are displayed.&#xD;
Only patients with non-missing assessment at the respective visit were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Main Period: Cohort 1</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Main Period: Cohort 2</title>
            <description>Minimum Dose IFX-1 (400 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O3">
            <title>Main Period: Cohort 3</title>
            <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O4">
            <title>Main Period: Cohort 4</title>
            <description>Medium Dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O5">
            <title>Main Period: Cohort 5</title>
            <description>High Dose IFX-1 (1200 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O6">
            <title>Extension Period: Cohort 3</title>
            <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O7">
            <title>Extension Period: Cohort 4</title>
            <description>Low dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Modified Sartorius Score (mSS) From Day 1.</title>
          <description>The absolute change from Day 1 will be analyzed by descriptive statistics by time point. The mSS is a summation of HS lesions based on a number of factors including anatomical region, number and type of lesions, distance between relevant lesions and lesions clearly separated by normal skin in each region measured as HS clinical parameters. The scale title for mSS is points. The mSS has a minimum value of 0 and no upper limit. The higher the score the more severe is the disease/worse is the outcome.</description>
          <population>For the Main Period the full analysis set was used for the analysis and results of Week 16 are displayed.&#xD;
For the Extension Period the safety analysis set was used for the analysis and results of week 44 are displayed.&#xD;
Only patients with non-missing assessment at the respective visit were analyzed.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="31"/>
                <count group_id="O6" value="64"/>
                <count group_id="O7" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.4" spread="30.78"/>
                    <measurement group_id="O2" value="-17.5" spread="48.43"/>
                    <measurement group_id="O3" value="-29.4" spread="32.35"/>
                    <measurement group_id="O4" value="-22.9" spread="52.00"/>
                    <measurement group_id="O5" value="-35.2" spread="101.91"/>
                    <measurement group_id="O6" value="-47.9" spread="70.87"/>
                    <measurement group_id="O7" value="-27.5" spread="45.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Patient's Global Assessment of Skin Pain From Day 1.</title>
        <description>The absolute changes from baseline were analyzed by descriptive statistics by time point. The Numeric Rating Scale (NRS) was used to assess the worst skin pain due to HS. The scale title for the NRS is points. Ratings for this item range from a minimum of 0 points (no skin pain) to a maximum of 10 points (skin pain as bad as you can imagine). The higher the score the more severe the disease/worse is the outcome.</description>
        <time_frame>From Day 1 until Day 309</time_frame>
        <population>For the Main Period the full analysis set was used for the analysis and results of Week 16 are displayed.&#xD;
For the Extension Period the safety analysis set was used for the analysis and results of week 44 are displayed.&#xD;
Only patients with non-missing assessment at the respective visit were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Main Period: Cohort 1</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Main Period: Cohort 2</title>
            <description>Minimum Dose IFX-1 (400 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O3">
            <title>Main Period: Cohort 3</title>
            <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O4">
            <title>Main Period: Cohort 4</title>
            <description>Medium Dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O5">
            <title>Main Period: Cohort 5</title>
            <description>High Dose IFX-1 (1200 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O6">
            <title>Extension Period: Cohort 3</title>
            <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O7">
            <title>Extension Period: Cohort 4</title>
            <description>Low dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Patient's Global Assessment of Skin Pain From Day 1.</title>
          <description>The absolute changes from baseline were analyzed by descriptive statistics by time point. The Numeric Rating Scale (NRS) was used to assess the worst skin pain due to HS. The scale title for the NRS is points. Ratings for this item range from a minimum of 0 points (no skin pain) to a maximum of 10 points (skin pain as bad as you can imagine). The higher the score the more severe the disease/worse is the outcome.</description>
          <population>For the Main Period the full analysis set was used for the analysis and results of Week 16 are displayed.&#xD;
For the Extension Period the safety analysis set was used for the analysis and results of week 44 are displayed.&#xD;
Only patients with non-missing assessment at the respective visit were analyzed.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="24"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="32"/>
                <count group_id="O7" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="2.82"/>
                    <measurement group_id="O2" value="-0.1" spread="2.68"/>
                    <measurement group_id="O3" value="-0.7" spread="2.37"/>
                    <measurement group_id="O4" value="-1.5" spread="2.92"/>
                    <measurement group_id="O5" value="-1.8" spread="3.03"/>
                    <measurement group_id="O6" value="-1.5" spread="2.94"/>
                    <measurement group_id="O7" value="-1.3" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving NRS30</title>
        <description>This is a segmented numeric version of the visual analog scale in which a respondent selects a whole number (0-10) that best reflects the intensity of their pain. The scale title for the NRS is points. The minimum score is 0 points (No skin pain), and the maximum score is 10 points (Skin pain as bad as you can imagine). The higher the score the more severe is the disease/worse is the outcome. The number of patients with at least 30% reduction and at least 1 point reduction from Day 1 in Patients Global Assessment of Skin Pain are displayed. The analysis is based on the worst skin pain the patients reported at the respective visits.</description>
        <time_frame>From Day 1 until Day 309</time_frame>
        <population>For the Main Period the full analysis set was used for the analysis and results of Week 16 are displayed.&#xD;
For the Extension Period the safety analysis set was used for the analysis and results of week 44 are displayed.&#xD;
Only patients with non-missing assessment at the respective visit were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Main Period: Cohort 1</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Main Period: Cohort 2</title>
            <description>Minimum Dose IFX-1 (400 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O3">
            <title>Main Period: Cohort 3</title>
            <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O4">
            <title>Main Period: Cohort 4</title>
            <description>Medium Dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O5">
            <title>Main Period: Cohort 5</title>
            <description>High Dose IFX-1 (1200 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O6">
            <title>Extension Period: Cohort 3</title>
            <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O7">
            <title>Extension Period: Cohort 4</title>
            <description>Low dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving NRS30</title>
          <description>This is a segmented numeric version of the visual analog scale in which a respondent selects a whole number (0-10) that best reflects the intensity of their pain. The scale title for the NRS is points. The minimum score is 0 points (No skin pain), and the maximum score is 10 points (Skin pain as bad as you can imagine). The higher the score the more severe is the disease/worse is the outcome. The number of patients with at least 30% reduction and at least 1 point reduction from Day 1 in Patients Global Assessment of Skin Pain are displayed. The analysis is based on the worst skin pain the patients reported at the respective visits.</description>
          <population>For the Main Period the full analysis set was used for the analysis and results of Week 16 are displayed.&#xD;
For the Extension Period the safety analysis set was used for the analysis and results of week 44 are displayed.&#xD;
Only patients with non-missing assessment at the respective visit were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving NRS50.</title>
        <description>This is a segmented numeric version of the visual analog scale in which a respondent selects a whole number (0-10) that best reflects the intensity of their pain. The scale title for NRS is points. The minimum score is 0 points (No skin pain), and the maximum score is 10 points (Skin pain as bad as you can imagine). The higher the score the more severe is the disease/worse is the outcome. The number of patients with at least 50% reduction and at least 1 point reduction from Day 1 in Patients Global Assessment of Skin Pain are displayed. The analysis is based on the worst skin pain the patients reported at the respective visits.</description>
        <time_frame>From Day 1 until Day 309</time_frame>
        <population>For the Main Period the full analysis set was used for the analysis and results of Week 16 are displayed.&#xD;
For the Extension Period the safety analysis set was used for the analysis and results of week 44 are displayed.&#xD;
Only patients with non-missing assessment at the respective visit were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Main Period: Cohort 1</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Main Period: Cohort 2</title>
            <description>Minimum Dose IFX-1 (400 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O3">
            <title>Main Period: Cohort 3</title>
            <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O4">
            <title>Main Period: Cohort 4</title>
            <description>Medium Dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O5">
            <title>Main Period: Cohort 5</title>
            <description>High Dose IFX-1 (1200 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O6">
            <title>Extension Period: Cohort 3</title>
            <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O7">
            <title>Extension Period: Cohort 4</title>
            <description>Low dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving NRS50.</title>
          <description>This is a segmented numeric version of the visual analog scale in which a respondent selects a whole number (0-10) that best reflects the intensity of their pain. The scale title for NRS is points. The minimum score is 0 points (No skin pain), and the maximum score is 10 points (Skin pain as bad as you can imagine). The higher the score the more severe is the disease/worse is the outcome. The number of patients with at least 50% reduction and at least 1 point reduction from Day 1 in Patients Global Assessment of Skin Pain are displayed. The analysis is based on the worst skin pain the patients reported at the respective visits.</description>
          <population>For the Main Period the full analysis set was used for the analysis and results of Week 16 are displayed.&#xD;
For the Extension Period the safety analysis set was used for the analysis and results of week 44 are displayed.&#xD;
Only patients with non-missing assessment at the respective visit were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="7"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change in Dermatology Life Quality Index (DLQI) Score From Day 1.</title>
        <description>The changes from Day 1 will be analyzed by descriptive statistics by time point. A score is documented for each of the 10 DLQI items, ranging from 0 to 3 for each item. The scale title for DLQI is points. The total score is the sum of the responses to all 10 DLQI items, ranging from the minimum of 0 points to the maximum of 30 points. A higher score corresponds to worse health related quality of life/outcome.</description>
        <time_frame>From Day 1 until Day 309</time_frame>
        <population>For the Main Period the full analysis set was used for the analysis and results of Week 16 are displayed.&#xD;
For the Extension Period the safety analysis set was used for the analysis and results of week 44 are displayed.&#xD;
Only patients with non-missing assessment at the respective visit were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Main Period: Cohort 1</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Main Period: Cohort 2</title>
            <description>Minimum Dose IFX-1 (400 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O3">
            <title>Main Period: Cohort 3</title>
            <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O4">
            <title>Main Period: Cohort 4</title>
            <description>Medium Dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O5">
            <title>Main Period: Cohort 5</title>
            <description>High Dose IFX-1 (1200 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O6">
            <title>Extension Period: Cohort 3</title>
            <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O7">
            <title>Extension Period: Cohort 4</title>
            <description>Low dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change in Dermatology Life Quality Index (DLQI) Score From Day 1.</title>
          <description>The changes from Day 1 will be analyzed by descriptive statistics by time point. A score is documented for each of the 10 DLQI items, ranging from 0 to 3 for each item. The scale title for DLQI is points. The total score is the sum of the responses to all 10 DLQI items, ranging from the minimum of 0 points to the maximum of 30 points. A higher score corresponds to worse health related quality of life/outcome.</description>
          <population>For the Main Period the full analysis set was used for the analysis and results of Week 16 are displayed.&#xD;
For the Extension Period the safety analysis set was used for the analysis and results of week 44 are displayed.&#xD;
Only patients with non-missing assessment at the respective visit were analyzed.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="59"/>
                <count group_id="O7" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="6.11"/>
                    <measurement group_id="O2" value="0.6" spread="6.39"/>
                    <measurement group_id="O3" value="-2.6" spread="7.19"/>
                    <measurement group_id="O4" value="-5.0" spread="5.90"/>
                    <measurement group_id="O5" value="-2.4" spread="5.24"/>
                    <measurement group_id="O6" value="-1.5" spread="7.18"/>
                    <measurement group_id="O7" value="-2.0" spread="6.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Parameters (Adverse Events) Will be Assessed.</title>
        <description>The number of patients with any treatment emergent adverse event (adverse events that started after first infusion of IMP) was analyzed by time point.</description>
        <time_frame>From Day 1 until Day 309</time_frame>
        <population>For the Main Period the safety analysis set was used for the analysis and results of Week 16 are displayed.&#xD;
For the Extension Period the safety analysis set was used for the analysis and results of week 44 are displayed.&#xD;
Only patients with non-missing assessment at the respective visit were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Main Period: Cohort 1</title>
            <description>Placebo&#xD;
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Main Period: Cohort 2</title>
            <description>Minimum Dose IFX-1 (400 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O3">
            <title>Main Period: Cohort 3</title>
            <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O4">
            <title>Main Period: Cohort 4</title>
            <description>Medium Dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O5">
            <title>Main Period: Cohort 5</title>
            <description>High Dose IFX-1 (1200 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O6">
            <title>Extension Period: Cohort 3</title>
            <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
          <group group_id="O7">
            <title>Extension Period: Cohort 4</title>
            <description>Low dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Parameters (Adverse Events) Will be Assessed.</title>
          <description>The number of patients with any treatment emergent adverse event (adverse events that started after first infusion of IMP) was analyzed by time point.</description>
          <population>For the Main Period the safety analysis set was used for the analysis and results of Week 16 are displayed.&#xD;
For the Extension Period the safety analysis set was used for the analysis and results of week 44 are displayed.&#xD;
Only patients with non-missing assessment at the respective visit were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="72"/>
                <count group_id="O7" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="24"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="39"/>
                    <measurement group_id="O7" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The observation period for Adverse Events (AEs) will start with confirmation of signed informed consent at Screening and ends at the Follow-up visit at Week 44.</time_frame>
      <desc>The safety data were analyzed separately for the Main Period and the Extension Period. AEs assessed up to and including Week 16 Visit were attributed to the Main Period. All safety data assessed after IFX-1 infusion at Week 16 were attributed to the Extension Period. Analysis were performed in the safety analysis set consisting of 177 patients. Of the 179 randomized patients, only 177 received treatment with IMP as 2 patients withdrew from the study before they were treated.</desc>
      <group_list>
        <group group_id="E1">
          <title>Main Period: Cohort 1</title>
          <description>Placebo&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="E2">
          <title>Main Period: Cohort 2</title>
          <description>Minimum Dose IFX-1 (400 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
        </group>
        <group group_id="E3">
          <title>Main Period: Cohort 3</title>
          <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
        </group>
        <group group_id="E4">
          <title>Main Period: Cohort 4</title>
          <description>Medium Dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
        </group>
        <group group_id="E5">
          <title>Main Period: Cohort 5</title>
          <description>High Dose IFX-1 (1200 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
        </group>
        <group group_id="E6">
          <title>Extension Period: Cohort 3</title>
          <description>Low dose IFX-1 (800 mg Q4W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
        </group>
        <group group_id="E7">
          <title>Extension Period: Cohort 4</title>
          <description>Medium Dose IFX-1 (800 mg Q2W)&#xD;
IFX-1: Single IV infusions of IFX-1 diluted in sodium chloride.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Cholangitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="49" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Korinna Pilz, MD, MSc</name_or_title>
      <organization>InflaRx N.V.</organization>
      <phone>+49 89 414 189 78 00</phone>
      <email>Korinna.Pilz@InflaRx.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

